CTN
NIDA-CTN-0134
Identifying Regional “Hotspots” and Potential Correlates of Precipitated Withdrawal During Buprenorphine Induction in Fentanyl Users Through Prescriber Survey Responses and Patient Urine Drug Test Results (Buprenorphine-Precipitated Withdrawal Hotspots and Correlates)
LaTrice Montgomery, Ph.D. , T. John Winhusen, Ph.D.
Jun 03, 2025
DTMC
NIDA-CSP-1033
Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder
Shwe Gyaw, M.D.
Jul 19, 2024
DTMC
NIDA-CPU-0010
Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine
Louis Cantilena, Jr., M.D, Ph.D.
Jun 03, 2020
DTMC
NIDA-CTO-0012
Phase 2, Double-Blind, Placebo-Controlled Trial Of Tiagabine For The Treatment Of Cocaine Dependence
Eugene Somoza, M.D.
Jan 15, 2019
DTMC
NIDA-CSP-1021
Double-Blind, Placebo-Controlled Multi-Center Trial Of Baclofen For The Treatment Of Cocaine Dependence
Liza Gorgon, M.A.
May 07, 2018
DTMC
NIDA-CSP-1019
Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System For The Treatment Of Cocaine Dependence
Ahmed Elkashef, M.D. , Paul J. Fudala, Ph.D.
May 07, 2018
DTMC
NIDA-MDS-0003
Phase I, Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Cocaine And Ethanol And Oral Disulfiram
John D. Roache, Ph.D.
Dec 21, 2017
DTMC
NIDA-CTO-0007
Phase 2, Double-Blind, Placebo-Controlled Trial Of Cabergoline For The Treatment Of Cocaine Dependence
Steven Shoptaw, Ph.D. , Thomas F. Newton, M.D.
Dec 21, 2017
DTMC
NIDA-CPU-0005
Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers.
Louis Cantilena, Jr., M.D, Ph.D.
May 23, 2017
DTMC
NIDA-CPU-0004
Study of Interactions Between GBR 12909 and Cocaine
Kathryn Cunningham, Ph.D. , John Grabowski, Ph.D.
May 23, 2017
DTMC
NIDA-CPU-0003
Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681
Louis Cantilena, Jr., M.D, Ph.D.
May 23, 2017
DTMC
NIDA-CPU-0002
Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers
Louis Cantilena, Jr., M.D, Ph.D.
May 23, 2017
DTMC
NIDA-CTO-0006
Cocaine-Metyrapone Interaction Study
Bonita Singal, M.D. , T. John Winhusen, Ph.D.
Aug 01, 2016
DTMC
NIDA-CTO-0005
Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence
John D. Roache, Ph.D.
Aug 01, 2016
DTMC
NIDA-CTO-0003
Assessment Of Potential Interactions Between Intravenous Cocaine And Tolcapone
Thomas F. Newton, M.D.
Aug 01, 2016
DTMC
NIDA-CTO-0002
Safety Evaluation Of Cocaine Treatment Medication, Modafinil: Interactions With Intravenous Cocaine
Robert J. Malcolm, M.D. , C. Lindsay DeVane, Pharm.D.
Aug 01, 2016
DTMC
NIDA-MDS-0004
Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For The Treatment Of Cocaine Dependence
Domenic Ciraulo, M.D.
Sep 02, 2015
DTMC
NIDA-CTO-0001
Phase 2, Double-Blind, Placebo-Controlled Trial Of Reserpine For The Treatment Of Cocaine Dependence
Eugene Somoza, M.D.
Dec 04, 2014
CTN
NIDA-CTN-0052
A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC)
T. John Winhusen, Ph.D.
May 14, 2014
CTN
NIDA-CTN-0048
Cocaine Use Reduction with Buprenorphine (CURB)
Walter Ling, M.D.
Apr 24, 2015